Association of vitamin D and platelet-to-lymphocyte ratio in treatment escalation risk for newly diagnosed Crohn’s disease adults

Table 2 Association of baseline VD deficiency with Infliximab and/or immunosuppressants usage in newly diagnosed CD patients

VD status	n	person- months	Events	Crude model		Adjusted model*
VD status	n	person- months	(%)	HR (95% CI)	P	HR (95% CI)	P
VD deficiency
No	23	89	8 (34.8)	Ref	—	Ref	—
Yes	85	391	46 (54.12)	1.46 (0.69–3.10)	0.320	3.22 (1.24–8.35)	0.016
VD levels
Q1	27	88	17 (63.0)	Ref	—	Ref	—
Q2	28	78	15 (53.6)	1.08 (0.54–2.17)	0.830	0.65 (0.24–1.75)	0.392
Q3	26	179	12 (46.2)	0.50 (0.23–1.07)	0.072	0.55 (0.20–1.56)	0.263
Q4	27	135	10 (37.0)	0.51 (0.23–1.13)	0.099	0.26 (0.09–0.76)	0.014
				P for trend = 0.031		P for trend = 0.014

*Adjusted for age of onset, sex, region, smoking, season of vitamin D measurement, disease location, disease behavior, occupation, BMI, CDAI, EIM and history of perianal surgery

ISSN: 1475-2891